Aurobindo Pharma’s arm receives warning letter from USFDA for New Jersey facility

22 Oct 2020 Evaluate

Aurobindo Pharma’s wholly owned step-down subsidiary -- AuroLife Pharma LLC has received a warning letter from US Food & Drug Administration (USFDA) for its oral solid manufacturing facility situated at Dayton, New Jersey. The company believes that the existing business from this facility will not be impacted. The Company will be engaging with the regulator and are fully committed in resolving this issue at the earliest.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1176.65 -40.80 (-3.35%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×